Membranous Expression of Secreted Frizzled-Related Protein 4 Predicts for Good Prognosis in Localized Prostate Cancer and Inhibits PC3 Cellular Proliferation in Vitro

Clinical Cancer Research

Volumn 10, Issue 2, 2004, Pages 615-625

  Horvath, Lisa G ^a   Henshall, Susan M ^a   Kench, James G ^a,b   Saunders, Darren N ^a   Lee, C Soon ^c   Golovsky, David ^a   Brenner, Phillip C ^a   O'Neill, Gordon F ^a   Kooner, Raji ^a   Stricker, Phillip D ^a   Grygiel, John J ^a   Sutherland, Robert L ^a,d  

^a ST VINCENT S HOSPITAL   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; FRIZZLED PROTEIN; FRIZZLED RELATED PROTEIN 4; GLYCOGEN SYNTHASE KINASE 3BETA; POLYCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; WNT PROTEIN;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER RECURRENCE; CANCER SURVIVAL; CARBOXY TERMINAL SEQUENCE; CELL MEMBRANE; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN PC 3; CONTROLLED STUDY; CYTOPLASM; DISEASE ASSOCIATION; FOLLOW UP; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; SCORING SYSTEM;

ADOLESCENT; ADULT; AGED; CELL DIVISION; CELL LINE, TUMOR; CELL MEMBRANE; COHORT STUDIES; CYTOPLASM; DISEASE-FREE SURVIVAL; DNA, COMPLEMENTARY; GENETIC VECTORS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MICROSCOPY, FLUORESCENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PEPTIDES; PHENOTYPE; PHOSPHORYLATION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS; RECURRENCE; RNA, MESSENGER; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; WNT PROTEINS;

EID: 10744233346     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-0707-03     Document Type: Article

References (53)

1. Tracey, E. A., and Supramaniam, R. Cancer in New South Wales: Incidence and Mortality 2000 Featuring Projections to 2010 for Selected Sites. Sydney, Australia: The Cancer Council NSW, 2002.
2. Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., and Thun, M. J. Cancer statistics, 2003. CA Cancer J. Clin., 53: 5-26, 2003.
3. Partin, A. W., Kattan, M. W., Subong, E. N., Walsh, P. C., Wojno, K. J., Oesterling, J. E., Scardino, P. T., and Pearson, J. D. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA, 277: 1445-1451, 1997.
4. Graefen, M., Karakiewicz, P. I., Cagiannos, I., Quinn, D. I., Henshall, S. M., Grygiel, J. J., Sutherland, R. L., Stricker, P. D., Klein, E., Kupelian, P., Skinner, D. G., Lieskovsky, G., Bochner, B., Huland, H., Hammerer, P. G., Haese, A., Erberdobler, A., Estham, J. A., de Kernion, J., Cangiano, T., Schroder, F. H., Wildhagen, M. F., van der Kwast, T. H., Scardino, P. T., and Kattan, M. W. International validation of a pre-operative nomogram for prostate cancer recurrence after radical prostatectomy. J. Clin. Oncol., 20: 3206-3212, 2002.
5. Dhanasekaran, S. M., Barrette, T. R., Ghosh, D., Shah, R., Varambally, S., Kurachi, K., Pienta, K. J., Rubin, M. A., and Chinnaiyan, A. M. Delineation of prognostic biomarkers in prostate cancer. Nature (Lond.), 412: 822-826, 2001.
6. Singh, D., Febbo, P. G., Ross, K., Jackson, D. G., Manola, J., Ladd, C., Tamayo, P., Renshaw, A. A., D'Amico, A. V., Richie, J. P., Lander, E. S., Loda, M., Kantoff, P. W., Golub, T. R., and Sellers, W. R. Gene expression correlates of clinical prostate cancer behaviour. Cancer Cell, 1: 203-209, 2002.
7. Luo, J. H., Yu, Y. P., Cieply, K., Lin, F., DeFlavia, P., Dhir, R., Finkelstein, S., Michalopoulos, G., and Becich, M. Gene expression analysis of prostate cancers. Mol. Carcinog., 33: 25-35, 2002.
8. Nusse, R., and Varmus, H. E. Wnt genes. Cell, 69: 1073-1087, 1992.
9. Polakis, P. Wnt signaling and cancer. Genes Dev., 14: 1837-1851, 2000.
10. Miller, J. R. The Wnts. Genome Biol., 3: 3001.1-3001.15, 2001.
11. Malbon, C. C., Wang, H., and Moon, R. T. Wnt signaling and heterotrimeric G-proteins: strange bedfellows or a classic romance? Biochem. Biophys. Res. Commun., 287: 589-593, 2001.
12. Shtutman, M., Zhurinsky, J., Simcha, I., Albanese, C., D'Amico, M., Pestelli, R., and Ben-Ze'ev, A. The cyclin D1 gene is a target of the β-catenin/LEF1 pathway. Proc. Natl. Acad. Sci. USA, 96: 5522-5527, 1999.
13. He, T. C., Sparks, A. B., Rago, C., Hermeking, H., Zawel, L., da Costa, L. T., Morin, P. J., Vogelstein, B., and Kinzler, K. W. Identification of c-MYC as a target of the APC pathway. Science (Wash. DC), 281: 1509-1512, 1998.
14. Weeraratna, A. T., Jiang, Y., Hostetter, G., Rosenblatt, K., Duray, P., Bittner, M., and Trent, J. M. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell, 1: 279-288, 2002.
15. 2+/calmodulin-depedent protein kinase II is stimulated by Wnt and Frizzled homologs and promotes ventral cell fates in Xenopus. J. Biol. Chem., 275: 12701-12711, 2000.
16. 2+ pathways. Oncogene, 18: 7860-7872, 1999.
17. Lin, K., Wang, S., Julius, M. A., Kitajewski, J., Moos, M., and Luyten, F. P. The cysteine-rich frizzled domain of Frzb-1 is required and sufficient for modulation of wnt signaling. Proc. Natl. Acad. Sci. USA, 94: 11196-11200, 1997.
18. Uren, A., Reichsman, F., Anest, V., Taylor, W. G., Muraiso, K., Bottaro, D. P., Cumberledge, S., and Rubin, J. S. Secreted frizzled-related protein-1 binds directly to wingless and is a biphasic modulator of Wnt signaling. J. Biol. Chem., 275: 4374-4382, 2000.
19. Bafico, A., Gazit, A., Pramila, T., Finch, P. W., Yaniv, A., and Aaronson, S. A. Interaction of frizzled related protein (FRP) with wnt ligands and the frizzled receptor suggests alternative mechanisms for FRP inhibition of wnt signaling. J. Biol. Chem., 274: 16180-16187, 1999.
20. Yang, F., Li, X., Sharma, M., Sasaki, C. Y., Longo, D. L., Lim, B., and Sun, Z. Linking β-catenin to androgen-signaling pathway. J. Biol. Chem., 277: 11336-11344, 2002.
21. Truica, C. I., Byers, S., and Gelmann, E. P. β-Catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res., 60: 4709-4713, 2000.
22. Chesire, D. R., Ewing, C. M., Gage, W. R., and Isaacs, W. B. In vitro evidence for complex modes of nuclear β-catenin signaling during prostate growth and tumorigenesis. Oncogene, 21: 2629-2694, 2002.
23. Gounari, F., Signoretti, S., Bronson, R., Klein, L., Sellers, W. R., Kum, J., Siermann, A., Taketo, M. M., von Boehmer, H., and Khazaie, K. Stabilization of β-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelium. Oncogene, 21: 4099-4107, 2002.
24. Sharma, M., Chuang, W. W., and Sun, Z. Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3β inhibition and nuclear β-catenin accumulation. J. Biol. Chem., 277: 30935-30941, 2002.
25. Iozzo, R. V., Eichstetter, I., and Danielson, K. G. Aberrant expression of the growth factor Wnt-5A in human malignancy. Cancer Res., 55: 3495-3499, 1995.
26. Phillips, S. M., Morton, D. G., Lee, S. J., Wallace, D. M., and Neoptolemos, J. P. Loss of heterozygosity of the retinoblastoma and adenomatous polyposis susceptibility gene loci and in chromosomes 10p, 10q and 16q in human prostate cancer. Br. J. Urol., 73: 390-395, 1994.
27. Watanabe, M., Kakiuchi, H., Kato, H., Shiraishi, T., Yatani, R., Sugimura, T., and Nagao, M. APC gene mutations in human prostate cancer. Jpn. J. Clin. Oncol., 26: 77-81, 1996.
28. Quinn, D. I., Henshall, S. M., Haynes, A. M., Brenner, P. C., Kooner, R., Golovsky, D., O'Neill, G., Turner, J. J., Delprado, W., Finlayson, J. F., Sutherland, R. L., Grygiel, J. J., and Stricker, P. D. Prognostic significance of pathological features in localized prostate cancer treated with radical prostatectomy: implications for staging systems and predictive models. J. Clin. Oncol., 19: 3692-3705, 2001.
29. Kononen, J., Bubendorf, L., Kallioniemi, A., Barlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihiatsch, M. J., Sauter, G., and Kallioniemi, O.-P. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med., 4: 844-847, 1998.
30. McNeal, J. E. Prostate. In: S. S. Sternberg (ed.), Histology for Pathologists, pp. 997-1018. Philadelphia/New York: Lippincott-Raven, 1997.
31. Horvath, L. G., Henshall, S. M., Lee, C. S., Head, D. R., Quinn, D. I., Makela, S., Delprado, W., Golovsky, D., Brenner, P. C., O'Neill, G., Kooner, R., Stricker, P. D., Grygiel, J. J., Gustafsson, J. A., and Sutherland, R. L. Frequent loss of estrogen receptor-β expression in prostate cancer. Cancer Res., 61: 5331-5335, 2001.
32. Kaighn, M. E., Narayan, K. S., Ohnuki, Y., Lechner, J. F., and Jones, L. W. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Investig. Urol., 17: 16-23, 1979.
33. Abu-Jawdeh, G., Comella, N., Tomita, Y., Brown, L. F., Tognazzi, K., Sokol, S. Y., and Kocher, O. Differential expression of frpHE: a novel human stromal protein of the secreted Frizzled gene family, during the endometrial cycle and malignancy. Lab. Investig., 79: 439-447, 1999.
34. Wolf, V., Ke, G., Dharmarajan, A. M., Bielke, W., Artuso, L., Saurer, S., and Friis, R. DDC-4, an apoptosis-associated gene, is a secreted frizzled relative. FEBS Lett., 417: 385-389, 1997.
35. Schumann, H., Holtz, J., Zerkowski, H. R., and Hatzfeld, M. Expression of secreted frizzled related proteins 3 and 4 in human ventricular myocardium correlates with apoptosis related gene expression. Cardiovasc. Res., 45: 720-728, 2000.
36. James, I. E., Kumar, S., Barnes, M. R., Gress, C. J., Hand, A. T., Dodds, R. A., Connor, J. R., Bradley, B. R., Campbell, D. A., Grabill, S. E., Williams, K., Blake, S. M., Gowen, M., and Lark, M. W. FrzB-2: a human secreted frizzled-related protein with a potential role in chondrocyte apoptosis. Osteoarthr. Cart., 8: 452-463, 2000.
37. Fujita, M., Ogawa, S., Fukuoka, H., Tsukui, T., Nemoto, N., Tsutsumi, O., Ouchi, Y., and Inoue, S. Differential expression of secreted frizzled-related protein 4 in decidual cells during pregnancy. J. Mol. Endocrinol., 28: 213-223, 2002.
38. Tebar, M., Destree, O., de Vree, W. J. A., and ten Have-Opbroek, A. A. W. Expression of Tcf/Lef and sFrp and localization of β-catenin in the developing mouse lung. Mech. Dev., 109: 437-440, 2001.
39. Wong, S. C. C., Lo, S. F. E., Lee, K. C., Yam, J. W. P., Chan, J. K. C., and Hsiao, W. L. W. Expression of frizzled-related protein and Wnt-signaling molecules in invasive human breast tumours. J. Pathol., 196: 145-153, 2002.
40. Melkonyan, H. S., Chang, W. C., Shapiro, J. P., Mahadevappa, M., Fitzpatrick, P. A., Kiefer, M. C., Tomei, L. D., and Umansky, S. R. SARPs: a family of secreted apoptosis-related proteins. Proc. Natl. Acad. Sci. USA, 94: 13636-13641, 1997.
41. Zhou, Z., Wang, J., Han, X., Zhou, J., and Linder, S. Up-regulation of human secreted frizzled homolog in apoptosis and its downregulation in breast tumours. Int. J. Cancer, 78: 95-99, 1998.
42. Roth, W., Wild-Bode, C., Platten, M., Grimmel, C., Melkonyan, H. S., Dichgans, J., and Weller, M. Secreted frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells. Oncogene, 19: 4210-4220, 2000.
43. Ugolini, F., Charafe-Jauffret, E., Bardou, V. J., Geneix, J., Adelaide, J., Labat-Moleur, F., Penault-Llorca, F., Longy, M., Jacquemier, J., Birnbaum, D., and Pebusque, M. J. WNT pathway and mammary carcinogenesis: loss of expression of candidate tumor suppressor gene SFRP1 in most invasive carcinomas except of the medullary type. Oncogene, 20: 5810-5817, 2001.
44. Bui, T. D., Rankin, J., Smith, K., Huguet, E. L., Ruben, S., Strachan, T., Harris, A. L., and Lindsay, S. A novel human Wnt gene. WNT10B, maps to 12q13 and is expressed in human breast carcinomas. Oncogene, 14: 1249-1253, 1997.
45. Bui, T. D., Zhang, L., Rees, M. C., Bicknell, R., and Harris, A. L. Expression and hormone regulation of Wnt2, 3, 4, 5a, 7a, 7b and 10b in normal human endometrium and endometrial carcinoma. Br. J. Cancer, 75: 1131-1136, 1997.
46. Rhee, C. S., Sen, M., Lu, D., Wu, C., Leoni, L., Rubin, J., Corr, M., and Carson, D. A. Wnt and frizzled receptors as potential targets for immunotherapy in head and neck squamous cell carcinomas. Oncogene, 21: 6598-6605, 2002.
47. Holcombe, R. F., Marsh, J. L., Waterman, M. L., Lin, F., Milovanovic, T., and Truong, T. Expression of wnt ligands and frizzled receptors in colonic mucosa and in colon carcinoma. Mol. Pathol., 55: 220-226, 2002.
48. Polakis, P. The oncogenic activation of β-catenin. Curr. Opin. Genet. Dev., 9: 15-21, 1999.
49. Voeller, H. J., Truica, C. I., and Gelmann, E. P. β-Catenin mutations in human prostate cancer. Cancer Res., 58: 2520-2523, 1998.
50. Chesire, D. R., Ewing, C. M., Sauvageot, J., Bova, G. S., and Isaacs, W. B. Detection and analysis of β-catenin mutations in prostate cancer. Prostate, 45: 323-334, 2000.
51. Lin, S. Y., Xia, W., Wang, J. C., Kwong, K. Y., Spohn, B., Wen, Y., Pestell, R. G., and Hung, M. C. β-Catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc. Natl. Acad. Sci. USA, 97: 4262-4266, 2000.
52. De Marzo, A. M., Knudsen, B., Chan-Tack, K., and Epstein, J. I. E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens. Urology, 53: 707-713, 1999.
53. Civenni, G., Holbro, T., and Hynes, N. E. Wnt1 and Wnt 5A induce cyclin D1 expression through ErbB1 transactivation in HC11 mammary epithelial cells. EMBO Rep., 4: 166-171, 2003.